

LIVER TUMOR MARKER SEQUENCES

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. provisional application Serial No. 60/396,626, filed on July 17, 2002, which is herein incorporated by reference in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0002] This invention was made with U.S. Government Support from the following agency: NIH, Grant No. CA22484. The U.S. Government has certain rights in the invention.

BACKGROUND OF THE INVENTION

[0003] Primary liver cancer is the fifth most common cancer worldwide with approximately half a million cases reported in 1990. Hepatocellular carcinoma (HCC) accounts for 80% of all liver cancer and the rates of HCC have increased by over 70% in the last two decades in the U.S. The fatality ratio (mortality/incidence) of liver cancer is approximately 1, indicating that the majority of patients live less than a year. Late diagnosis due to lack of clinical symptoms is one of the main reasons for the high fatality ratio.

[0004] Liver cancer can result from both viral infection and chemical exposure. Known risk factors include hepatitis B and C virus infection and exposure to aflatoxin β 1. It is not known whether distinct routes to liver cancer affect the same or different cellular pathways. No mutational model has yet been developed for liver cancer as it has been for other cancers such as colon cancer. The molecular events that precede neoplastic transformation of the liver are not well understood. With no clearly identified cause, successful treatment options are lacking. In fact, the specific genes that are deregulated in liver cancer have not yet been enumerated. This is a critical first step in developing a successful strategy for treating liver cancer.

[0005] There is a pressing need to understand the molecular events associated with the development of liver cancer, both in humans and in animal model systems where liver cancer is extensively studied, and to provide diagnostic and therapeutic reagents for treating same.

BRIEF SUMMARY OF THE INVENTION

[0006] The invention is summarized in that polypeptides of the invention are found in liver tumor cells and in cells from preneoplastic liver foci in human and non-human animals at

levels higher than are found in regenerating or quiescent normal liver tissue. This finding has been confirmed in human breast, colon and kidney cancer cell lines. As a result of this differential overexpression, the polypeptides, as well as polynucleotides that encode the polypeptides, are diagnostic markers for cancer in general, especially liver, breast, colon and kidney cancer, in a human or non-human animal.

[0007] In one aspect, the present invention relates to an isolated polypeptide containing an amino acid sequence of SEQ ID NO:2, an amino acid sequence that is at least 70% identical to SEQ ID NO:2 over the length of SEQ ID NO:2, an amino acid sequence of amino acid 22 to amino acid 439 of SEQ ID NO:2 (secreted portion of SEQ ID NO:2), an amino acid sequence that is at least about 68% identical to amino acid 22 to amino acid 439 of SEQ ID NO:2 over the length of amino acid 22 to amino acid 439 of SEQ ID NO:2, an amino acid sequence of SEQ ID NO:4, an amino acid sequence that is at least 70% identical to SEQ ID NO:4 over the length of SEQ ID NO:4, an amino acid sequence of amino acid 22 to amino acid 400 of SEQ ID NO:4 (secreted portion of SEQ ID NO:4), an amino acid sequence that is at least about 68% identical to amino acid 22 to amino acid 400 of SEQ ID NO:4 over the length of amino acid 22 to amino acid 400 of SEQ ID NO:4. The percentage identity of sequences is determined using the Blosum62 alignment method.

[0008] In another aspect, the invention also relates to an isolated nucleic acid containing a polynucleotide that encodes a polypeptide of the invention, to a complement of the polynucleotide, or to a polynucleotide that is at least about 80% identical, more preferably 90% identical, and still more preferably 95% identical to an aforementioned polynucleotide of the invention, using the Wilbur-Lipman DNA Alignment method. A polynucleotide that encodes a polypeptide of the invention can include but is not limited to SEQ ID NO:1 from nucleotide 25 to nucleotide 1341, which encodes SEQ ID NO:2, as well as SEQ ID NO:3 from nucleotide 1 to nucleotide 1200, which encodes SEQ ID NO:4. SEQ ID NO:3, predicted by the inventors to represent a coding region on human chromosome 15 (contig Hs15_10351), is 82.4% identical to the polypeptide-encoding portion of SEQ ID NO:1 using the Wilbur-Lipman DNA Alignment method.

[0009] In another aspect, a polynucleotide of the invention is engineered into a genetic construct downstream from a heterologous promoter not natively upstream of the polynucleotide that directs transcription of the polynucleotide. The genetic construct is introduced into a host cell that supports transcription of the polynucleotide and translation of the encoded polypeptide which can then be purified using methods known to those skilled in the art. Alternatively, the

construct comprising a polynucleotide of the invention is provided in an *in vitro* transcription/translation system for producing the encoded polypeptide.

[00010] In yet another aspect, the present invention provides a host cell transfected with a genetic construct of the invention.

[00011] In still another aspect, the invention is an antibody that specifically binds to a polypeptide of the invention.

[00012] In yet another aspect, the invention is a method for identifying an agent that modulates the expression of a polypeptide of the invention (e.g., an inducer or suppressor). The method includes the steps of exposing a cell that contains a polynucleotide of the invention under the control of its native promoter, measuring the expression of the polynucleotide in the cell, and comparing the expression to that in a control cell that is not exposed to the test agent. A higher or lower than the expression in the control cell indicates that the agent can modulate the expression of the polynucleotide. The expression can be measured and compared at either the mRNA level or the protein level. Preferably, a liver, breast, colon or kidney cell (cancerous or normal) is used in the method. More preferably, a human or murine liver, breast, colon or kidney cell is used.

[00013] In still another aspect, the present invention is a method of diagnosing cancer or preneoplastic development in a tissue or organ of a human or non-human animal by measuring the expression of a polypeptide of the invention in cells of the tissue or organ obtained from a region suspected of cancer or preneoplastic development, and comparing the expression to a normal standard, wherein a higher than normal expression indicates cancer or preneoplastic development in the suspected region. A skilled artisan can readily establish a normal standard. For example, it can be the expression level in normal cells of the same tissue or organ in the same animal, or it can be an expression level range established by testing normal cells of the same tissue or organ of other animals of the same species. The expression can be measured and compared at either the mRNA level or protein level.

[00014] In a related aspect, the present invention is a method for identifying a candidate human or non-human animal for further cancer screening, where the method includes, in one embodiment, the step of determining the level of a polypeptide of the invention in a blood or blood-derived sample from the animal, whereby the animal is identified as a candidate for further cancer screening when the level exceeds either a normal range established by the same animal during a period that is tumor-free in the tissue or organ, or a normal range established by other animals of the same species that are tumor-free in the tissue or organ. In another

embodiment, the method takes advantage of the expected secretion of the polypeptide and the development of antibodies to the polypeptide in a human or non-human animal that overexpresses the polypeptide in the cancerous or preneoplastic tissue or organ. The method includes the step of determining the level of an antibody to the polypeptide in a blood or blood-derived sample from the animal, whereby the animal is identified as a candidate for further cancer screening when the antibody level exceeds either a normal range established by the same animal during a period that is tumor-free in the tissue or organ, or a normal range established by other animals of the same species that are tumor-free in the tissue or organ. It is understood that individuals free of cancer or preneoplastic development in the tissue or organ may not develop an antibody to the polypeptide. Thus, the normal range for the level of the antibody can be zero.

[00015] In still another aspect, the invention relates to a kit suitable for use in a method for determining the level of a polypeptide or polynucleotide of the invention, where the kit contains at least one of an antibody specifically directed to an epitope on a polypeptide of the invention and a polynucleotide that hybridizes to a polynucleotide of the invention, as well as at least one control sample component for which the relative or absolute amount of the polynucleotide or polypeptide of the present invention is known, the control sample component being selected from liver cancer cells, preneoplastic liver cells, normal liver cells, breast cancer cells, normal breast cells, colon cancer cells, normal colon cells, kidney cancer cells, normal kidney cells, an extract of any of the foregoing cells, a blood sample from a human or non-human animal, and a blood-derived sample from a human or non-human animal.

[00016] It is an object of the present invention to provide a polynucleotide and a polypeptide that are differentially expressed in preneoplastic or cancer cells and normal regenerating or quiescent cells in a tissue or organ of a human and non-human animal.

[00017] Other objects, features and advantages of the present invention will become apparent upon consideration of the following detailed description of the invention.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

[00018] Fig. 1 shows the cloning of CRG-L2. a) RT-PCR analysis of *CRG-L2* in mouse liver tissues. Because the C3H/HeJ mice used in these studies are inbred, all untreated mice are genetically identical. Accordingly, we have never observed any differences in CRG-L2 expression in comparison of individual normal mice. Therefore, quiescent, regenerating, and newborn RNA samples were prepared from several mice and then pooled so that the same pooled RNA samples could be used in multiple experiments. Quiescent and regenerating

samples are a combination of four livers and newborn samples are a combination of eight livers. However, it is known that tumors display heterogeneous genetic and molecular profiles. Therefore, to take into consideration these possible differences, the tumor samples used in our experiments are from individual mice. b) mRNA structure of *CRG-L2*. Alignment of the 5' and 3' RACE products suggest that *CRG-L2* mRNA can contain one of three alternative 3'UTRs. c) Northern blot hybridization of *CRG-L2* in quiescent liver and four individual liver tumors. Four bands were detected at 2.4, 3.0, 5.5, and 10 kb mRNAs. The three smaller mRNAs correspond to clones A, B, and C. A fourth band, D, was not cloned probably due to inefficient PCR through a long 3' UTR. d) The *CRG-L2* open reading frame was aligned to mouse chromosome 9 (31 cM). Exons are represented by black boxes. The distance between some of the exons is estimated since there are gaps between the contigs in the genome and these gaps are represented by a > sign. *CRG-L2* is localized within chromosome 15q21.2 of the human genome and a similar intron/exon structure is suggested by comparing the mouse cDNA to the human genome.

[00019] Fig. 2 shows structural features of the *CRG-L2* protein. a) *CRG-L2* cDNA encodes a protein of 48 kD containing two collagen domains and an olfactomedin domain. b) Hydrophobicity analysis of the putative *CRG-L2* protein with the Kyle-Doolittle algorithm. Positive values represent hydrophilic regions and negative values represent hydrophobic regions.

[00020] Fig. 3 shows that *CRG-L2* expression is increased in human hepatocellular carcinomas. Top panel is a phosphoimage of the RT-PCR results measuring *CRG-L2* mRNA and middle panel is a longer autoradiographic exposure. Equal loading was confirmed by analysis of *GAPDH* mRNA. All HCC were classified as moderately differentiated.

[00021] Fig. 4 shows that *CRG-L2* expression is restricted in normal tissues. *CRG-L2* mRNA was amplified in multiple mouse (a) and human (b) tissues using Multiple Tissue cDNA Panels. Aliquots of the PCR products were taken out at the indicated cycles.

DETAILED DESCRIPTION OF THE INVENTION

[00022] Liver cancer is generally studied in animal model systems, preferably in rodent systems, where certain strains are bred for high susceptibility to liver tumors. C3H/HeJ mice are highly susceptible to liver tumors after induction with diethylnitrosamine (DEN). To identify polynucleotide sequences or genes that show differential expression in liver tumor cells as compared to normal liver cells, gene expression differences between liver tumors and a regenerating liver were determined using representational difference analysis (RDA: Lisitsyn, et al., Science 259:946 (1993), incorporated by reference as if set forth herein in its entirety).

[00023] In this application, the applicants disclose polypeptides from murine animals (SEQ ID NO:2) and humans (SEQ ID NO:4) that are upregulated in cells and cell extracts from human and murine liver tumors and liver preneoplastic tissues, relative to quiescent and regenerating normal liver cells. The polypeptide is therefore given the name human or murine Cancer Related Gene - Liver 2 (CRG-L2). CRG-L2 overexpression was also found in human liver, breast, colon and kidney cancer cell lines. Thus, despite of its name indicative of liver origin, it is believed to be overexpressed in other types of cancer and preneoplastic cells in general, especially breast, colon and kidney cancer and preneoplastic cells.

[00024] Using the Blosum62 alignment method, the human and murine CRG-L2s are found to be 76% identical. It is expected that CRG-L2s from other animals, e.g., other mammals, are at least 70% identical to either the human or murine CRG-L2 if compared using the same alignment method. Hydrophobic sequences are present within the first 30 amino acids of SEQ ID NO:2 and SEQ ID NO:4. Based on information obtained from other proteins with leader sequences, the serine at amino acid position 21 of both SEQ ID NO:2 and SEQ ID NO:4 is believed to be the cleavage site of a leader sequence for the secretion of both of the CRG-L2s. Accordingly, it is believed that when amino acids 1-21 are cleaved, the remaining amino acid sequences of SEQ ID NO:2 and SEQ ID NO:4 can be secreted from cells. Corresponding leader sequences on other CRG-L2s can be readily identified by a skilled artisan. Depending on the variability of the leader sequences among CRG-L2s, the percentage of identity among the secreted sequences may be about 3% higher or lower than the overall 70% identity. Generally speaking, it is expected that the secreted portion of CRG-L2s in other animals, e.g., other mammals, are at least about 68% identical to either the secreted portion of the human or that of the murine CRG-L2.

[00025] Also disclosed are polynucleotides that encode the polypeptides of the invention (e.g., the full length and the secreted CRG-L2s), which can include, without limitation, mRNA, single or double stranded DNA, cDNA and the like. In addition to the primary murine cDNA product disclosed as SEQ ID NO:1, two additional variant murine cDNAs that are believed to derive from alternative 3' untranslated regions were also obtained. The variant murine cDNA molecules differ from SEQ ID NO:1 in the 3' untranslated portion of the molecules, commencing respectively at nucleotide 1937 and at nucleotide 2342, as shown in the Sequence Listing. SEQ ID NO:3 discloses a sequence from human Chromosome 15 that encodes the human CRG-L2 of SEQ ID NO:4.

[00026] Further, the invention provides materials and methods for detecting expression (and changes in expression) of the polypeptides and of the polynucleotides that encode the polypeptides, thereby facilitating use as a diagnostic marker for cancer and preneoplastic development and as a system for assessing putative therapeutic agents. As described in detail in the example below, since the CRG-L2 either belongs or is similar to the family of cancer-testis antigens, it is expected that a patient will display an immune response to CRG-L2 when it is overexpressed in preneoplastic and cancerous tissues. Therefore, detecting or measuring the level of an antibody to CRG-L2 in a blood or blood-derived sample from a patient provides another diagnostic tool.

[00027] Structurally, the murine CRG-L2 protein (SEQ ID NO:2) contains 439 amino acids and has a predicted molecular weight of about 47.5 kDA. Using the Simple Modular Architecture Research Tool (<http://smart.embl-heidelberg.de/>), it was determined that the murine CRG-L2 includes two collagen domains in the 5' region (corresponding to amino acids 29-88 and 89-149 of SEQ ID NO:2, respectively) and a large olfactomedin domain near the C-terminus (corresponding to amino acids 189-433 of SEQ ID NO:2). The human protein also contains two putative collagen domains and one olfactomedin domain at amino acids 27-85, 86-145, and 177-395 of SEQ ID NO:4, respectively. Olfactomedin-related proteins are secreted glycoproteins having conserved C terminal motifs. It is anticipated that CRG-L2 can be secreted into the blood and an increase in blood CRG-L2 level over normal levels is diagnostic of cancer and preneoplastic development. Preferably, the diagnostic blood CRG-L2 level is set to be at least about 5%, more preferably at least about 10%, and most preferably at least about 25% over a normal level.

[00028] The term "isolated nucleic acid" or "isolated polypeptide" used in the specification and claims of the present invention means a nucleic acid or polypeptide isolated from its natural environment or prepared using synthetic methods such as those known to one of ordinary skill in the art. Complete purification is not required in either case. Amino acid and nucleotide sequences that flank a polypeptide or polynucleotide that occurs in nature, respectively, can but need not be absent from the isolated form. The polypeptides and nucleic acids of the invention can be isolated and purified from normally associated material in conventional ways such that in the purified preparation the polypeptide or nucleic acid is the predominant species in the preparation. At the very least, the degree of purification is such that the extraneous material in the preparation does not interfere with use of the polypeptide or nucleic acid of the invention in the manner disclosed herein. The polypeptide or nucleic acid is

preferably at least about 85% pure, more preferably at least about 95% pure and most preferably at least about 99% pure.

[00029] Further, an isolated nucleic acid has a structure that is not identical to that of any naturally occurring polynucleotide or to that of any fragment of a naturally occurring genomic polynucleotide spanning more than three separate genes. An isolated nucleic acid also includes, without limitation, (a) a polynucleotide having a sequence of a naturally occurring genomic or extrachromosomal nucleic acid molecule but which is not flanked by the coding sequences that flank the sequence in its natural position; (b) a polynucleotide incorporated into a vector or into a prokaryote or eukaryote genome such that the resulting molecule is not identical to any naturally occurring vector or genomic DNA; (c) a separate molecule such as a cDNA, a genomic fragment, a fragment produced by polymerase chain reaction (PCR), or a restriction fragment; and (d) a recombinant nucleotide sequence that is part of a hybrid gene, i.e., a gene encoding a fusion protein. Specifically excluded from this definition are polynucleotides present in mixtures of clones, e.g., as these occur in a DNA library such as a cDNA or genomic DNA library. An isolated nucleic acid can be modified or unmodified DNA or RNA, whether fully or partially single-stranded or double-stranded or even triple-stranded. A nucleic acid can be chemically or enzymatically modified and can include so-called non-standard bases such as inosine.

[00030] The nucleotide sequences of the invention can be introduced into, and expressed in, host cells which can be prokaryotic (such as bacterial) cells or eukaryotic (such as yeast, insect, amphibian or mammalian) cells whereupon the transcription of polynucleotide and the properties of the encoded polypeptides can be assessed.

[00031] The disclosure of the CRG-L2 sequences that are upregulated in liver tumor and preneoplastic cells, and in human breast, colon and kidney cancer cell lines provides a means for identifying (*in vivo* or *in vitro*) candidates for further testing as preventive and therapeutic agents. For example, animal cells that contain a CRG-L2 sequence under the control of its native promoter can be exposed to a test agent and the effect of the test agent on the CRG-L2's expression at the mRNA or protein level relative to that of untreated controls can be measured. Alternatively, the level of expression can be assessed in biological samples taken directly from a human or non-human tissue. Presumably, an anti-tumor agent can bring down the mRNA and protein level in tumor cells. Accordingly, an agent that demonstrates such an activity is a good candidate for further testing for anti-tumor efficacy.

[00032] The presence and level of such a differentially expressed protein can be readily discerned using antibodies directed to an epitope on the protein using well known methods, such as an ELISA method. It is well within the skill of one of ordinary skill in the art to generate such antibodies. The presence and level of mRNA for the protein can be measured using methods for hybridizing nucleic acids (including, without limitation, RNA, DNA, and cDNA). Such methods are generally known to those skilled in the art, but are enabled by the disclosure herein of a tumor-specific sequence. Examples of such methods include but are not limited to RT-PCR amplification, Northern blot and Southern blot.

[00033] Given the disclosure herein of polynucleotides that encode CRG-L2 of human, murine and other animal species, one of ordinary skill in the art knows how to design primers for use in RT-PCR analysis and probes for Northern and Southern blot. The Example below describes a method of using RT-PCR to measure CRG-L2 mRNA level in liver tumor cells, liver preneoplastic cells and normal liver cells. The RT-PCR amplified a fragment of CRG-L2 cDNA (SEQ ID NO:1) and its noted 3' end variants, and the mRNA level in liver tumor and preneoplastic cells was observed to be higher than that in normal liver cells. Accordingly, a suitable CRG-L2 sequence for amplifying or probing in analyzing differential CRG-L2 mRNA levels is one that corresponds to a fragment shared by all three CRG-L2 cDNA sequences. A CRG-L2 mRNA sequence that corresponds to a fragment unique to the longer 3' untranslated sequence variants could also be used to analyze differential CRG-L2 mRNA expression since Northern analysis has shown that all three mRNAs are differentially expressed in liver tumor and preneoplastic cells relative to normal liver cells.

[00034] A skilled artisan understands that the polynucleotides disclosed herein can contain additional nucleotides at the 5'-end, 3'-end or both that do not affect the function of the polynucleotides in terms of their uses contemplated herein. The additional nucleotides can but do not have to assist in the cloning, detection and purification procedures associated with the use of the polynucleotides. Similarly, a skilled artisan understands that the polypeptides disclosed herein can contain additional amino acid sequences at the N- or C-terminus or both that do not affect the function of the polypeptides. The additional amino acid sequences can but do not have to assist in purification, detection, or stabilization of the polypeptides.

[00035] Further, a skilled artisan understands that polynucleotide and polypeptide sequences presented herein can vary somewhat, whether as a result, e.g., of sequencing error or allelic variation or duplication, from the sequence presented while still retaining their essential nature, that is, higher expression level in tumor and preneoplastic cells relative to normal cells.

Further, the polynucleotides of the invention include conservatively modified variants of the sequences presented herein, complementary sequences, and splice variants. In view of the known degeneracy in the genetic code, the proteins or polypeptides disclosed can also be encoded by a large number of other polynucleotide sequences, all of which are within the scope of the invention. Polynucleotide sequences that are at least 80% identical to the polynucleotide sequences that encode the polypeptide sequences disclosed herein can be used as hybridization probes for coding sequences and are thus within the scope of the present invention. The polynucleotides and polypeptides of the invention include, without limitation, polymorphic variants, alleles, mutants, and interspecies homologs that (1) are expressed at higher level in tumor and preneoplastic cells, especially in liver, breast, colon and kidney tumor and preneoplastic cells, (2) bind to antibodies raised against the coding region of the disclosed polypeptides, (3) specifically hybridize under stringent or moderately stringent hybridization conditions to a polynucleotide that encodes a polypeptide of the present invention, or (4) are amplified by primers that amplify a polynucleotide that encodes a polypeptide of the present invention.

[00036] Exemplary stringent hybridization conditions include 50% formamide, 5X SSC and 1% SDS incubated at 42°C, or 5X SSC and 1% SDS incubated at 65°C, followed by washing in 0.2X SSC and 0.1% SDS at 65°C. Exemplary moderately stringent hybridization conditions include 40% formamide, 1M NaCl and 1% SDS incubated at 37°C followed by washing in 1X SSC at 45°C. These conditions are merely exemplary as one skilled in the art is readily able to discern stringent from moderately stringent hybridization conditions.

[00037] Moreover, the sequences of the invention also encompass substitutions, additions and deletions of the sequences presented where the change affects one or a few amino acids in the presented polypeptide sequences, without substantial effect upon the activity of the polypeptide, i.e., differential expression in cancer cells and preneoplastic cells relative to normal cells.

[00038] The present invention will be better understood upon consideration of the following non-limiting example.

EXAMPLE

Materials and Methods

[00039] *Rapid Amplification of cDNA Ends (RACE).* Rapid amplification of cDNA ends (RACE) was performed in both directions using the SMART cDNA amplification kit (Clontech)

from mouse liver tumor polyA RNA. 5' and 3' RACE were performed using the gene-specific primers, GSP-A [5'-GCATGGCAAGAACAGACTGG-3'] (SEQ ID NO:5) and GSP-B [5'-GGATGAGAAGGGCATCTGGA-3'] (SEQ ID NO:6). 5' and 3' RACE products that were identified with the corresponding GSP primer were gel extracted and cloned into TOPO-TA vector (Invitrogen). Cloned products were sequenced by Big Dye (ABI) in the McArdle Laboratory Sequencing Facility (University of Wisconsin-Madison).

[00040] *RNA Analysis.* For analysis of murine CRG-L2 mRNA, total RNA was extracted from liver using guanidine thiocyanate/CsCl as described previously in (Lukas *et al.*, 1999, incorporated by reference in its entirety). PolyA mRNA was isolated from 250 µg of total RNA using Oligotex mRNA Kit (Qiagen). RT-PCR was performed as described previously (Graveel *et al.*, 2001, incorporated by reference in its entirety) with primers, RDA-3a [5'-CAACAACCTGGCTTAGAGC-3'] (SEQ ID NO:7) and RDA-3b [5'-GCCATCTGATGCTCTATCC-3'] (SEQ ID NO:8).

[00041] For Northern blot hybridization, polyA RNA samples (2 µg) were prepared and electrophoresed as described previously (Lukas *et al.*, 1999). Gel was soaked in 5 volumes of water for 5 min and then transferred overnight to a GeneScreen (NEN Life Science Products) membrane in 10X SSC. Membrane was UV crosslinked twice (120 mJ) and baked in a vacuum for 2 h at 80°C. Membrane was prehybridized at 42°C overnight in hybridization solution [50% formamide, 5X Denhardt's solution, 1% SDS, 10% dextran sulfate, 1 mg sonicated salmon sperm DNA (boiled), 5X standard saline phosphate with EDTA (SSPE)]. Probes were labeled by nick translation (Rigby *et al.*, 1977). A fragment of CRG-L2 (nucleotides 188-1243 of SEQ ID NO:1) was released with EcoRI from the pCR-TOPO4 vector. ³²P-labeled probe was added to the hybridization buffer and hybridized overnight at 42°C. Blots were washed at RT in 2X SSPE for 30 min and at 65°C for 45 min in 2X SSPE, 2%SDS. Signals were visualized by autoradiography or phosphoimager.

[00042] For analysis of CRG-L2 in human tissue, RT-PCR was performed for 25 cycles with primers hCRGL2a [5'-CATGGCAAGAACAGACTGGG-3'] (SEQ ID NO:9) and hCRGL2b [5'-GCCAGGAAACATCCCAAACCTC-3'] (SEQ ID NO:10) and 10 µl of the reaction was electrophoresed on a 1% agarose/EtBr gel. The gels were soaked in 1X TAE for 5 min, denatured for 30 min [1.5M NaCl, 0.5M NaOH], and neutralized for 30 min [1.5M NaCl, 0.5M Tris (pH 7.2), 1 mM EDTA (pH 8.0)]. DNA was transferred to a Hybond N membrane (Amersham) with 20X SSPE overnight. The membrane was baked for 30 min at 80°C in a vacuum oven and UV crosslinked twice (120 mJ). The membrane was prehybridized at 42°C

for 3 h in hybridization solution [50% formamide, 5% Denhardt's, 3.4X SSPE, 10% dextran sulfate, 5% SDS, 1% sarkosyl, 100 mg sonicated salmon sperm DNA (SSS), 100 mg boiled SSS]. Probes were labeled by nick translation (CRG-L2 fragment, nucleotides 188-1243 of SEQ ID NO:1) and added to the hybridization solution. Membranes were hybridized overnight at 42°C and were washed for 20 min at RT in 2X SSPE, 0.1% SDS and for 2 h at 65°C in 0.5X SSPE, 0.2% SDS. Signals were visualized by autoradiography and phosphoimager. All primers used in this study were synthesized at the University of Wisconsin-Madison Biotechnology Center.

[00043] *In Situ Hybridization.* *In situ* hybridization was performed as described previously (Micales & Lyons, 2001, incorporated by reference in its entirety) with the CRG-L2 plasmid 5-2 (containing nucleotides 82-1243 of SEQ ID NO:1) and AFP plasmid (containing nucleotides 726-1401 of the AFP mRNA) in the plasmid pCR4-TOPO (Invitrogen). Sense and antisense probes were synthesized using T7 or SP6 with a MAXIscript kit (Ambion) to generate ³⁵S uridine triphosphate (UTP)-labeled riboprobes. Hybridized sections were exposed to emulsion (NTB-2; Eastman Kodak) in the dark for 2 weeks before developing. After they were developed, the sections were counterstained with hematoxylin, mounted and viewed under both light-field and dark-field illumination.

[00044] *Multiple Tissue cDNA Panel.* The mouse and human tissue cDNA panels (Clontech) were screened following manufacturer's instructions. After 28 cycles, 5 µl aliquots were removed at various timepoints. The mouse panel was screened with primers, GSP-970 and GSP-1241 (see RACE section for primer sequences), and the human panel was screened with primers, hCRGL2-C [5'-AGGGCCCACCAGGGCAGAAG-3'] (SEQ ID NO:11) and hCRGL2-D [5'-ACATGCTTGCTGCCGAGGG-3'] (SEQ ID NO:12).

[00045] *Human Tissue.* Human tissue and serum was procured from the University of Wisconsin Surgical Pathology department, National Disease Research Interchange, and the NCI Cooperative Human Tissue Network. All samples analyzed were primary tissues. As required by our IRB protocol, the identity of the patients was unknown. The excess tissue was frozen after surgery and stored at -70°C.

Results

[00046] *Cloning of CRG-L2 using Rapid Amplification of cDNA Ends.* By representational difference analysis, a 282 bp fragment of an uncharacterized mRNA was isolated (Graveel *et al.*, 2001). Using RT-PCR analysis with primers located in the RDA

fragment, this mRNA showed elevated expression in mouse liver tumors as compared to quiescent, regenerating, or newborn livers (Fig. 1a). The low level of expression in the regenerating livers suggested the possibility that the increased expression was tumor-specific and would not occur in non-tumorigenic proliferative states of human liver, such as cirrhosis or hepatitis. The complete cDNA was obtained via Rapid Amplification of cDNA Ends (RACE). Products from both 5' and 3' RACE were subcloned and sequenced. Sequencing the 3' RACE products revealed three fragments which were identical at their 5' ends due to the fixed location of the gene-specific primer. However, these fragments differed at their 3' ends, with the longer fragments containing, but extending past, the sequence of the shorter fragments. Each fragment contained a polyA tail at its 3' end, indicating that there are multiple polyadenylation sites. The 5' RACE products were all identical. By conceptually combining the 5' and 3' RACE products, three mRNAs were identified that contained alternative 3'UTRs (Fig. 1b). The putative start codon is at nucleotide 25 and the putative stop codon at nucleotide 1344 (see SEQ ID NO:1). Because it was known that this mRNA was upregulated in murine liver tumors yet the function was unknown, this novel mRNA was named Cancer Related Gene - Liver 2 (CRG-L2).

[00047] To confirm the presence of all three of the murine *CRG-L2* mRNAs and to determine which mRNA is predominantly expressed, a Northern blot hybridization was performed using mRNA from quiescent livers and four individual liver tumors. A 1 kb fragment of the *CRG-L2* open reading frame was used as a probe and four mRNAs were observed (Fig. 1c). The 2.4, 3.0, and 5.5 kb mRNAs (designated as A, B, and C respectively in Fig. 1c) correspond to the 1967, 2380, and 4365 bp cloned cDNAs. The size of the observed mRNAs was longer than the RACE cDNA products due to the polyA tails. A fourth mRNA (designated as D) of approximately 10 kb was faintly detected but was not cloned via RACE presumably due to its length. As expected based on previous RT-PCR results, none of the mRNAs were observed in the quiescent livers. The 5.5 kb mRNA was the predominant form in the liver tumors and thus the sequence of the 4365 nt mRNA has been deposited in Genbank as CRG-L2 (AF548022, SEQ ID NO:1).

[00048] To determine the structure of the *CRG-L2* gene, the sequence of the mRNA was aligned to mouse chromosome 9 (31 cM) using the Jackson Laboratory and Ensembl Mouse Genome browsers (Fig. 1d). The *CRG-L2* gene is comprised of 10 exons and nine introns that cover a minimum of 59 kb. An exact measure of the *CRG-L2* gene is not yet possible because there are gaps between the contigs that contain the introns between exons 1 and 2 and exons 8 and 9.

[00049] The amino acid sequence (SEQ ID NO:2) of the 47.5 kDa CRG-L2 protein was analyzed by the SMART analysis program (Fig. 2a) and was found to contain two collagen domains near the amino terminus (amino acids 29-88 and 89-149 of SEQ ID NO:2) and a large olfactomedin domain within the C terminus (amino acid 189-433 of SEQ ID NO:2). Hydrophobicity analysis of the CRG-L2 protein revealed hydrophobic sequences within the first thirty amino acids of the amino terminus, which represent a leader sequence, suggesting that CRG-L2 is secreted (Fig. 2b). A serine was also present at amino acid 21 which is anticipated to be the cleavage site of the leader sequence. Regions of high hydrophobicity were also present in the carboxy terminal region, which is anticipated to represent transmembrane domains.

[00050] The human sequence for CRG-L2 was pieced together by using the UCSC Human Genome Working Draft (<http://genome.ucsc.edu/>) to align the sequences. The resulting cDNA sequence is presented as SEQ ID NO:3 and the putative amino acid sequence is presented as SEQ ID NO:4. Using the Wilbur-Lipman DNA alignment method the mouse and human open reading frame (ORF) are found to be 82.4% identical. Using the Blosum62 alignment method the mouse and human predicted protein products are found to be 76% identical. Like the murine protein, the human protein contains two putative collagen domains and one olfactomedin domain, located at amino acids 27-85, 86-145, and 177-395 of SEQ ID NO:4, respectively.

[00051] *CRG-L2* is localized within chromosome 15q21.2 of the human genome and a similar intron/exon structure is suggested by comparing the mouse cDNA to the human genome. In the human genome data base at NCBI, clone Hs15_10351 (Genbank Accession No. NT_010194), a contig from human chromosome 15, has areas of significant homology to the mouse cDNA sequences. Because this region of the human genome has not been finished in NCBI, the UCSC Human Genome Working Draft (<http://genome.ucsc.edu/>) was used to align the sequences in piecing together the human sequence for CRG-L2. First, exons of the human CRG-L2 gene were identified by aligning the mouse CRG-L2 ORF to the human genome using the NBLAST program. Next, the identified exons were spliced together and putative introns were excised to form SEQ ID NO:3. SEQ ID NO:4 shows a predicted polypeptide sequence encoded by SEQ ID NO:3. The skilled artisan will appreciate the possibility for some variation in the polynucleotide and polypeptide sequences arising from uncertainty at putative splice sites.

[00052] *CRG-L2 mRNA is upregulated in human hepatocellular carcinomas.* As noted above, regions of human chromosome 15 are highly similar to mouse *CRG-L2*. Based on this similarity, primers were designed to detect human *CRG-L2* mRNA. Using these human primers,

the level of expression of *CRG-L2* was measured in multiple human hepatocellular carcinomas and in normal livers. A combined method of RT-PCR and Southern blot hybridization was used to measure the levels of human *CRG-L2*. *CRG-L2* mRNA was amplified by RT-PCR for 25 cycles and the PCR products were transferred to a nylon membrane that was probed with a fragment of the murine *CRG-L2* open reading frame (nucleotides 188-1243 of SEQ ID NO:1). As shown in Fig. 3, *CRG-L2* mRNA is essentially undetectable in the normal liver samples but can be detected in all five hepatocellular carcinoma samples (middle panel). Extremely high expression is seen in HCC-2, as seen by the shorter exposure of the film (top panel). Accurate quantitation of the starting mRNA samples was verified by analysis of *GAPDH* mRNA.

[00053] *CRG-L2 is upregulated early in liver tumorigenesis.* A very important characteristic of a clinical marker for HCC would be early expression during liver tumor development. Because it is difficult to obtain samples corresponding to early states of liver tumors from human cancer patients, we investigated the timing of expression of *CRG-L2* using the DEN-treated mouse model. After a single administration of DEN to 12 day old mice, basophilic foci are visible by histological staining at 12 weeks of age. Sequential development of hyperplastic nodules, hepatocellular adenomas, and hepatocellular carcinomas is observed between 12 weeks and 32 weeks of age in male mice (Moore *et al.*, 1981; Vesselinovitch *et al.*, 1985). Therefore, we sacrificed the DEN-treated mice at 20 and 32 weeks of age. At 20 weeks of age, numerous preneoplastic lesions were visible throughout the liver and by 32 weeks the foci had progressed into hepatocellular adenomas/carcinomas (Hanigan *et al.*, 1988). Paraformaldehyde fixed sections from 20 and 32 week livers were probed with either an antisense (to detect *CRG-L2* mRNA) or sense (negative control) *CRG-L2* probe.

[00054] We began by analysis of the 32 week tumors because our RT-PCR results clearly showed that *CRG-L2* is upregulated at this stage. Although we expected to detect *CRG-L2* mRNA in the 32 week tumors, *in situ* hybridization can provide additional information that cannot be obtained by RT-PCR analysis. For example, tumor-specific genes may demonstrate a constant level of expression throughout a tumor or the expression can be localized to specific cell types or spatial locations (e.g. the periphery of the tumor). Using *in situ* hybridization, we observed that *CRG-L2* mRNA was upregulated in hepatocytes throughout the entire tumor. We note that *CRG-L2* was detected in only 69% (311/453) of the tumors examined using *in situ* hybridization but was detected in all seven tumors examined by RT-PCR (Fig. 1a). This could be due to the fact that only seven tumors were analyzed in Fig. 1a or because RT-PCR is more sensitive than *in situ* hybridization.

[00055] To determine if *CRG-L2* is upregulated at early stages of hepatocarcinogenesis, the expression of *CRG-L2* was examined in the preneoplastic foci using *in situ* hybridization. Interestingly, we found that *CRG-L2* mRNA can be detected in preneoplastic foci. The pattern of *CRG-L2* expression appears to be consistent throughout the focus with no localization within any individual region. We found that *CRG-L2* is highly upregulated in 55% of the foci (220/403) but that there is no obvious histological differences in those foci which do or do not express *CRG-L2*; e.g. *CRG-L2* is upregulated in both basophilic and eosinophilic foci and in foci with extensive fat or collagen deposits. *AFP* was found to be upregulated in 30% of preneoplastic foci (92/304) although the expression pattern was often restricted to various regions of the focus and not as uniformly distributed as *CRG-L2*. In other studies, *AFP* has been shown to be expressed in only 23% of 28 week old DEN-treated B6C3F1 mice (Koen *et al.*, 1983) and 24% of human hepatocellular carcinomas by immunohistochemistry (Borscheri *et al.*, 2001). In comparison to *AFP* in these studies, *CRG-L2* may be a more sensitive marker for the detection of early HCC.

[00056] *CRG-L2* displays restricted expression in normal tissues. A characteristic of a good clinical marker for HCC is tumor-specific expression; i.e. low expression in all normal tissues not just in the tissue from which the tumor is derived. Although *CRG-L2* mRNA was not detected in normal mouse liver, it was possible that the mRNA was expressed in other normal tissues. The expression of *CRG-L2* was examined in mouse and human tissues using a multiple tissue cDNA panel. Because performing high numbers of PCR cycles can sometimes obscure differential expression, aliquots of the PCR products were taken out after various cycles (30-34). We found that *CRG-L2* is primarily expressed in the mouse testis with moderate expression in skeletal muscle (Fig. 4a). In human tissues, *CRG-L2* was expressed primarily in the placenta (Fig. 4b). The pattern of *CRG-L2* expression, high in tumors, but normally expressed in testis and placenta, resembles expression patterns of genes known as cancer-testis antigens (CT antigen). Cancer-testis antigens are a group of genes classified by their exclusive expression in the testis and other reproductive tissues and diverse human cancers. The above findings suggest that *CRG-L2* is a potential CT antigen.

[00057] *CRG-L2 is a CT antigen.* The examination of *CRG-L2* expression revealed that *CRG-L2* mRNA is expressed at very low levels in all normal tissues except in the mouse testis and human placenta. Therefore, *CRG-L2* falls into a class of genes designated as cancer-testis antigens (CT antigen). The characteristics of CT antigens are a lack of expression in normal tissues, except reproductive tissues, and high levels of expression in a wide range of tumor

types. Currently there are more than ten genes identified that are CT antigens, one of which, PAGE, also shows high expression levels in the placenta (Brinkman *et al.*, 1998). Most CT antigens map to the X chromosome, but *SCP-1* (Türeci *et al.*, 1998), *CT9* (Scanlan *et al.*, 2000), and *OY-TES-1* (Ono *et al.*, 2001) map to other chromosomes, as does *CRG-L2*. CT antigens are intriguing therapeutic targets for immunotherapy because of their limited expression in normal tissues and the fact that the testis and placenta are immune-privileged sites. However, the biological function and the relationship to malignancy of most of these genes is unknown (Ono *et al.*, 2001; Scanlan *et al.*, 2002). With regard to CRG-L2, the protein structure indicates that CRG-L2 belongs to a family of olfactomedin-related proteins, which includes olfactomedin, myocilin/TIGR, noelin-1, and hGC-1. Olfactomedin-related genes have characteristic tissue-restricted expression patterns suggesting a specialized function for each protein (Richards *et al.*, 1998; Zhang *et al.*, 2002). Based on tissue localization of several olfactomedin family members and the function of TIGR/myocilin, it is possible that olfactomedin-related proteins play an important role in protein-protein interactions within the extracellular matrix (Kulkarni *et al.*, 2000). CRG-L2 also contains two collagen domains; proteins that contain collagen domains are also often involved in the structure of the extracellular matrix.

[00058] Our results clearly indicate that expression of *CRG-L2* is increased in tumors. This increased expression in tumors and restricted pattern of expression in normal tissues indicates that CRG-L2 is a tumor-specific antigen. It is thus anticipated that a patient will display an immunogenic response to CRG-L2, making CRG-L2 a marker that can be detected using blood samples to allow more cost-effective screening of a larger number of high risk patients.

[00059] The polynucleotide and polypeptide sequences disclosed herein provide a skilled artisan with the ability to assess using conventional methods the expression levels of the human CRG-L2 gene in an array of tissues and more specifically to monitor the expression of the gene in human liver regions suspected of liver cancer or preneoplastic development as compared to normal human liver tissue. Likewise, antibodies directed to a portion of the human protein can be produced and used as diagnostic agents for assessing protein levels in various human tissues including liver tumors. In addition, over-expressed CRG-L2 from liver tumor cells and preneoplastic liver cells is expected to be secreted into the blood and the blood level of this protein can be easily monitored by various methods known to one of ordinary skill in the art. A patient having liver cancer and preneoplastic development in the liver may also develop an

immune response to CRG-L2 and thus an antibody to CRG-L2 may be detected in the blood of the patient.

[00060] The present invention is not intended to be limited to the foregoing example, but rather to encompass all such variations and modifications as come within the scope of the appended claims.

REFERENCES

(All references listed below are herein incorporated by reference in their entirety)

- Borscheri, N., Roessner, A. & Roecken, C. (2001). *Am J Surg Pathol*, **25**, 1297-1303.
- Brinkman, U., Vasmatazis, G., Lee, B., Yerushalmi, N., Essand, M. & Pastan, I. (1998). *Proc Natl Acad Sci USA*, **95**, 10757-10762.
- Graveel, C.R., Jatkoa, T., Madore, S.J., Holt, A.L. & Farnham, P.J. (2001). *Oncogene*, **20**, 2704-2712.
- Hanigan, M.H., Kemp, C.J., Ginsler, J.J. & Drinkwater, N.R. (1988). *Carcinogenesis*, **9**, 885-890.
- Koen, H., Pugh, T.D., Nychka, D. & Goldfarb, S. (1983). *Cancer Res*, **43**, 702-708.
- Kulkarni, N., Karavanich, C.A., Atchley, W.R. & Anholt, R.R.H. (2000). *Genet. Res.*, **76**, 41-50.
- Lukas, E.R., Bartley, S.M., Graveel, C.R., Diaz, Z.M., Dyson, N., Harlow, E., Yamasaki, L. & Farnham, P.J. (1999). *Mol. Carcino.*, **25**, 295-303.
- Micales, B.K. & Lyons, G.E. (2001). *Methods*, **23**, 313-323.
- Moore, M.R., Drinkwater, N.R., Miller, E.C., Miller, J.A. & Pitot, H.C. (1981). *Cancer Res*, **41**, 1585-1593.
- Ono, T., Kurashige, T., Harada, N., Noguchi, Y., Saika, T., Niikawa, N., Aoe, M., Nakamura, S., Higashi, T., Hiraki, A., Wada, H., Kumon, H., Old, L. & Nakayama, E. (2001). *Proc. Natl. Acad. Sci. USA*, **98**, 3282-3287.
- Richards, J.E., Ritch, R., Lichter, P.R., Rozsa, F.W., Stringham, H.M., Caronia, R.M., Johnson, D., Abundo, G.P., Willcockson, J., Downs, C.A., Thompson, D.a., Musarella, M.A., Gupta,

- N., Othman, M.I., Torrez, D.M., Herman, S.B., Wong, D.J., Higashi, M. & Boehnke, M. (1998). *Ophthalmology*, **105**, 1698-1707.
- Rigby, P.W.J., Dieckmann, M., Rhoades, C. & Berg, P. (1977). *J. Mol. Biol.*, **113**, 237-251.
- Scanlan, M.J., Altorki, N.K., Gure, A.O., Williamson, B., Jungbluth, A., Chen, Y.T. & Old, L.J. (2000). *Cancer Lett*, **150**, 155-164.
- Scanlan, M.J., Gordon, C.M., Williamson, B., Lee, S.-Y., Chen, Y.-T., Stockert, E., Jungbluth, A., Ritter, G., Jäger, D., Jäger, E., Knuth, A. & Old, L.J. (2002). *Int. J. Cancer*, **98**, 485-492.
- Türeci, O., Sahin, U., Zwick, C., Koslowski, M., Seitz, G. & Pfreundschuh, M. (1998). *Proc Natl Acad Sci USA*, **95**, 5211-5216.
- Vesselinovitch, S.D., Hacker, H.J. & Bannasch, P. (1985). *Cancer Res*, **45**, 2774-2780.
- Zhang, J., Liu, W.-L., Tang, D.C., Chen, L., Wang, M., Pack, S.D., Zhuang, Z. & Rodgers, G.P. (2002). *Gene*, **283**, 83-93.